«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:

03

期数:

2003年2期

页码:

140-142

栏目:

出版日期:

2003-02-28

文章信息/Info

Title:

Intracavitary perfusion of Carboplation and Interferon by implanted pleural catheter for malignant pleural effusion　

作者:

梁莉　 马力文　 张淑兰　 张照辉　 王墨培　 贾廷珍

北京大学第三医院肿瘤治疗中心,北京,100083

Author(s):

Liang Li;  Ma Liwen;  Zhang Shulan;  et al.

The Center ofOncology, Peking UniversityThirdHospital,Beijing100083, China

关键词:

恶性胸腔积液 导管 卡铂 α-2b干扰素

Keywords:

　Malignant pleural effusion　Catheter　Carboplatin　α-2b Interferon

分类号:

R608;R561.305.3

文献标志码:

A

摘要:

目的探讨胸腔内置入单腔中心静脉导管化疗对恶性胸腔积液的价值. 方法观察组(n=17)胸腔内置入导管持续引流后腔内注入卡铂与α-2b干扰素,对照组(n=29)反复胸腔穿刺引流后腔内注入卡铂与α-2b干扰素.治疗后1月、3月及6月观察疗效,胸水变化参考WHO癌性渗液疗效判定标准. 结果观察组腔内治疗(2.2±1.9)次,对照组腔内治疗(5.3±1.3)次,两组比较差异有显著性(t=5.924,P=0.00).观察组治疗后1月、3月及6月,CR分别为10/16例、11/16例及10/15例,对照组分别为9/29例、11/29例及5/19例,观察组明显高于对照组(P值分别为0.043,0.050,0.020).治疗后1月、3月及6月,观察组总有效率分别为87.5%、87.5%、80.0%,对照组总有效率分别为62.5%、68.5%、66.7%,两组总有效率无明显差异(P值分别为0.356,0.114,0.178).观察组远期疗效较好,治疗后第6个月仍有10/15病例达到CR.两组出现的副作用差异无显著性(χ2=2.491,P=0.0114). 结论胸腔内置入中心静脉导管化疗达到CR的例数提高,可明显降低卡铂与α-2b干扰素联合治疗次数,副作用小.

Abstract:

Objective　To explore the value of center vein catheter thoracostomy in the chemotherapy of malignant pleural effusion.　 Methods　Carboplatin andα-2b Interferon were infused into pleural cavity by implanted center vein catheter in the group observation (n= 17). After repeated thoracocentesis, the same drugs were introduced into pleural cavity in the group control (n=29). At the end of the 1st, 3rd and 6th month after drug administration, follow-up was carried out to assess the response rates.　Results　At the end of the 1st, 3rd and 6th month after intrapleural therapies, the number of intrapleural therapies in the group observation was (2·2±1·9) times and in the group control (5·3±1·3)times, with statistically significant difference between the two groups (t=5·924,P=0·00). Numbers of complete remission (CR) in the group observation was 10 of 16, 11 of 16 and 10 of 15, respectively and in the group control 9 of 29, 11 of 29 and 5 of 19, respectively, producing significant difference (P=0·043, 0·050, 0·020, respectively). Overall response rates in the group observa- tion were 87·5%, 87·5% and 80·0%, respectively, while in control were 62·5%, 68·7% and 66·7%, respectively, without significant difference (P=0·356, 0·114, 0·178, respectively). Compared with the control, long-term follow-up (six months) showed higher re- sponse rates in the group observation: 10 of 15 patients remained CR at 6thmonth aftertherapies. No significant difference was seen in respect to adverse effects(χ2=2·491,P=0·114).　Conclusions　Intrapleural chemotherapy by center vein cathetermay increase CR and decrease application times of Carboplatin andα-2b Interferon in the treatment of malignant pleural effusion, with fewer side effects.

常用功能

更新日期/Last Update: 2014-06-10